Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | EVP & CHIEF FINANCIAL OFFICER | August 15, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TANDEM DIABETES CARE INC
Report date August 15, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,040 |
Ending reported balance
After 2026-08-15 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-08-15 · Exercise / conversion · Acquired 1,496 · Balance 50,895 Row 2 · 2026-08-15 · Tax withholding · Disposed 537 · Balance 50,358 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. Row 3 · 2026-08-15 · Exercise / conversion · Acquired 2,624 · Balance 52,982 Row 4 · 2026-08-15 · Tax withholding · Disposed 942 · Balance 52,040 F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 4,486 |
Reported balance
After 2026-08-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-15 · Exercise / conversion · Disposed 1,496 · Balance 4,486 F3: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan). F4: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F5: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 18,368 |
Reported balance
After 2026-08-15 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-15 · Exercise / conversion · Disposed 2,624 · Balance 18,368 F6: Awarded on May 30, 2025 pursuant to the 2023 Plan. F4: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan. F7: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan. |
| Common StockSEC Table I · non-derivative | IndirectLeigh A. Vosseller Trust | 25,580 |
Reported balance
Holding disclosure · report date 2026-08-15 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 25,580 F2: The securities are held by the Leigh A. Vosseller Trust dated January 17, 2010, of which Leigh Vosseller is the Trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld by the Issuer to satisfy tax withholding requirements upon the vesting of restricted stock units (RSUs). No shares were sold.
F2: The securities are held by the Leigh A. Vosseller Trust dated January 17, 2010, of which Leigh Vosseller is the Trustee.
F3: Awarded on May 23, 2024 pursuant to the Tandem Diabetes Care Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
F4: Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.
F5: One-third of the RSUs granted on May 23, 2024 vested on May 15, 2025, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
F6: Awarded on May 30, 2025 pursuant to the 2023 Plan.
F7: One-third of the RSUs granted on May 30, 2025 vested on May 15, 2026, with the remaining RSUs vesting in eight (8) equal quarterly installments thereafter, subject to the terms of the 2023 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 18, 2019 Filed Nov 19, 2019 00:12 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 8,300 | $65.27 | $541,741.00 |
DisclosureSEC source: 0001438133-19-000022 · wf-form4_157412235717003.xml · nonDerivative · entry 2 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,965 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2019, as amended on August 26, 2019. F3 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $65.74. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 00:12 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 10,000 | $2.59 | $25,900.00 |
DisclosureSEC source: 0001438133-19-000022 · wf-form4_157412235717003.xml · nonDerivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP & CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: . Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-19-030992 · doc4.xml · derivative · entry 5 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter. F7 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 10,000 | $70.45 | $704,500.00 |
DisclosureSEC source: 0001209191-19-030992 · doc4.xml · nonDerivative · entry 2 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,009 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2019. F3 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $70.35 to $70.60. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| May 16, 2019 Filed May 17, 2019 20:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 10,000 | $2.59 | $25,900.00 |
DisclosureSEC source: 0001209191-19-030992 · doc4.xml · nonDerivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| May 15, 2019 Filed May 17, 2019 20:44 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 1,256 | $16.93 | $21,264.08 |
DisclosureSEC source: 0001209191-19-030992 · doc4.xml · nonDerivative · entry 3 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,265 F4 · shares: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of November 16, 2018 through May 15, 2019. This transaction is also exempt under Rule 16b-3(c). Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionStock Option · Derivative | 10,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-19-027810 · doc4.xml · derivative · entry 4 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fifty percent (50%) of the underlying shares subject to the option vested on 12/1/2018, and the remaining shares shall vest in twelve (12) equal monthly installments thereafter. F6 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | SaleCommon Stock | 10,000 | $65.14 | $651,400.00 |
DisclosureSEC source: 0001209191-19-027810 · doc4.xml · nonDerivative · entry 2 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,009 F2 · kind: The shares were sold, pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2019. F3 · price: The price reported is the weighted average price. The shares were sold in multiple transactions at prices ranging from $65.00 to $65.28. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold. Read SEC document |
| May 03, 2019 Filed May 6, 2019 21:33 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | Exercise / conversionCommon Stock | 10,000 | $2.59 | $25,900.00 |
DisclosureSEC source: 0001209191-19-027810 · doc4.xml · nonDerivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| February 15, 2019 Filed Feb 20, 2019 21:12 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 105,000 | $0.00 Strike: $51.50 | $0.00 |
DisclosureSEC source: 0001209191-19-011506 · doc4.xml · derivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan. F2 · derivative.exercise_date: The option shall vest as to twenty-five percent (25%) of the underlying shares on 2/15/2020, and the remaining shares shall vest in thirty-six (36) equal monthly installments thereafter. F3 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 23:29 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantCommon Stock | 1,255 | $16.92 | $21,234.60 |
DisclosureSEC source: 0001209191-18-059313 · doc4.xml · nonDerivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,145 F1 · date: The reporting person is voluntarily reporting the acquisition of shares of common stock pursuant to the Tandem Diabetes Care, Inc. Amended and Restated 2013 Employee Stock Purchase Plan ("ESPP"), for the ESPP purchase period of June 15, 2018 through November 15, 2018. This transaction is also exempt under Rule 16b-3(c). F2 · date: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on June 15, 2018. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 22:57 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 100,000 | $0.00 Strike: $18.86 | $0.00 |
DisclosureSEC source: 0001209191-18-038177 · doc4.xml · derivative · entry 1 Vosseller Leigh · CIK 0001726322 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest as to 50% on 6/14/2019 and the remainder in 12 equal monthly installments thereafter F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.